Table 2.
Safety of M-M-R II in individuals ≥7 years of age
| Author, year | Study arm | N | Timeframe (AE) | Fever | Injection site reactions | Measles/rubella like rash |
|---|---|---|---|---|---|---|
| Abu-Elyazeed20 | M-M-R II | 457 | 0–42 days | 5.2% (defined as temperature ≥38°C) | 11.7% injection site redness; 11.5% injection site pain (day 0–3) |
0.4% |
| Diaz-Ortega15 | M-M-R II injection | 62 | 12 months | 6.45% (not defined) | NR | NR |
| Diaz-Ortega16 | NA | 100 | NR | NR | NR | NR |
| Gothefors18 | NA | 150 | 40 days | 8.7% (defined as temperature ≥38.1°C) | 33.3% injection site pain; 25.3% redness; 12.7% swelling (day 0–3) | NR |
| Sarno17 | M-M-R II delivered by standard syringe (either before or after reconstitutional buffer delivered by injection) | 40 | NR | 2.5% mild fever at 15 days (not defined) | 12.5% injection site soreness (within 15 days) |
NR |
| Dos Santos14 | NA | NR | NR | NR | NR | NR |
| Dos Santos21 | NA | 2216 | 30 days | 4.7% (not defined) | 2% injection site pain (within 30 days) | NR |
| Cassidy19 | HB (visit 1) M-M-R® II (visit 1) Td (visit 1) |
97 | 0–4 days | 2.2% (not defined) | NR | NR |
| HB (visit 1) M-M-R® II (at 4.5 months) Td (at 4.5 months) |
100 | 0–4 days | 0 | NR | NR |